[1] |
LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua.
Research progress in population pharmacokinetics of rituximab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
|
[2] |
LUO Mingjie, LIU Runhan, ZHOU Jie, WANG Zhenlei.
Comparison of common parameter estimation methods in NONMEM 7.5.1.: A case study of ibuprofen injection in Chinese healthy adult population
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 290-298.
|
[3] |
LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang.
Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
|
[4] |
YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong.
Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990.
|
[5] |
LIU Wei, XUE Junsheng, YU Zhiheng, WANG Ziyu, CHEN Rong, ZHOU Tianyan.
Interpretation of pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer guidance for industry
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 86-94.
|
[6] |
LIN Liangmo, FU Xiangjun, ZHONG Lili, WANG Hefang, WU Qiongshi, XIAO Jian.
Establishment of population pharmacokinetics model of vancomycin in patients with Neutropenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1014-1022.
|
[7] |
XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi.
Population pharmacokinetics of capecitabine in Chinese breast cancer patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
|
[8] |
LI Wenchao, BAI Xiangrong, LI Xiaoling, JIANG Dechun.
Population pharmacokinetics/pharmacodynamics of tigecycline in the treatment of different infectious diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1265-1272.
|
[9] |
GUO Xianzhong, LIN Rongfang, LIN Weiwei.
Development of software for individualizing dosage regimens of vancomycin based on population pharmacokinetics models
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 30-39.
|
[10] |
LI Jian, YANG Jinbo, WANG Yuzhu.
Discussion on the format and content of new drug population pharmacokinetic study report
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 546-549.
|
[11] |
XU Gaoqi, ZHANG Yiwen, ZHENG Xiaowei, LIU Yujia, LI Li, HUANG Ping.
Missed and remedial dosage regimens of erlotinib by Monte Carlo simulation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 540-545.
|
[12] |
CHEN Wenjun, RUAN Zourong, XIANG Xiaoqiang.
Development and application progress of physiologically based pharmacokinetic modeling and its combined use with other modeling methods
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 299-305.
|
[13] |
LI Jian, YANG Jinbo, WANG Yuzhu.
Applications of model-informed drug development (MIDD) on new drug research and development
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 1-8.
|
[14] |
LIU Simin, CAI Jun, LI Huixin, YANG Li, ZHAO Yan, ZHANG Jinping.
Research progress in population pharmacokinetics of voriconazole in adults
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1015-1023.
|
[15] |
WU Min, GUO Yiyun, XIE Haitang.
Population pharmacokinetics of tamoxifen in patients with breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 418-423.
|